Literature DB >> 32142965

Medical Management Strategies in Acute and Chronic Rhinosinusitis.

Seong H Cho1, Dennis Ledford1, Richard F Lockey2.   

Abstract

Chronic rhinosinusitis, historically, has been considered to be caused by upper airway anatomical abnormalities. However, today that concept has changed, for it is now recognized as an inflammatory disorder of the nasal and sinus mucosa. Acute rhinosinusitis is usually caused by a viral infection, whereas chronic rhinosinusitis is a persistent and heterogeneous inflammatory disorder with increased expression of type 1, 2, or 17 cytokines in the nasal and sinus mucosa, similar to that which occurs in asthma. Exacerbations are caused by aeroallergens in the allergic individual and irritants, pollutants, and viral/bacterial infections in all subjects. It may be categorized by phenotypes, examples of which include chronic rhinosinusitis with nasal polyps or chronic rhinosinusitis without nasal polyps. Defined endotypes are based on underlying pathophysiological mechanisms. Knowledge of chronic rhinosinusitis endotypes will optimize management by employing targeted medical therapies. Understanding that rhinosinusitis is a heterogeneous inflammatory disease has led to the identification of a variety of different predisposing conditions, new medical treatment options, and the concept that rhinosinusitis is primarily a medical problem.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Inflammatory disorder; Medical management; Nasal polyps; Rhinosinusitis

Mesh:

Year:  2020        PMID: 32142965      PMCID: PMC7700823          DOI: 10.1016/j.jaip.2020.02.020

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  47 in total

1.  Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures.

Authors:  Pravin Hissaria; William Smith; Peter J Wormald; James Taylor; Mathew Vadas; David Gillis; Frank Kette
Journal:  J Allergy Clin Immunol       Date:  2006-05-19       Impact factor: 10.793

2.  Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin.

Authors:  S Kudoh; A Azuma; M Yamamoto; T Izumi; M Ando
Journal:  Am J Respir Crit Care Med       Date:  1998-06       Impact factor: 21.405

3.  Effect of fluticasone in severe polyposis.

Authors:  V J Lund; J Flood; A P Sykes; D H Richards
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1998-05

Review 4.  Topical therapies for management of chronic rhinosinusitis: steroid implants.

Authors:  Joseph K Han; Robert C Kern
Journal:  Int Forum Allergy Rhinol       Date:  2019-05       Impact factor: 3.858

5.  Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis.

Authors:  K Holmberg; S Juliusson; B Balder; D L Smith; D H Richards; G Karlsson
Journal:  Ann Allergy Asthma Immunol       Date:  1997-03       Impact factor: 6.347

6.  Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps.

Authors:  Philippe Gevaert; Doris Lang-Loidolt; Andreas Lackner; Heinz Stammberger; Heribert Staudinger; Thibaut Van Zele; Gabriele Holtappels; Jan Tavernier; Paul van Cauwenberge; Claus Bachert
Journal:  J Allergy Clin Immunol       Date:  2006-09-26       Impact factor: 10.793

7.  The effectiveness of oxymetazoline plus intranasal steroid in the treatment of chronic rhinitis: A randomised controlled trial.

Authors:  Torpong Thongngarm; Paraya Assanasen; Panitan Pradubpongsa; Pongsakorn Tantilipikorn
Journal:  Asian Pac J Allergy Immunol       Date:  2016-03       Impact factor: 2.310

8.  Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania.

Authors:  Xiangdong Wang; Nan Zhang; Mingyu Bo; Gabriele Holtappels; Ming Zheng; Hongfei Lou; Hong Wang; Luo Zhang; Claus Bachert
Journal:  J Allergy Clin Immunol       Date:  2016-07-15       Impact factor: 10.793

9.  Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis.

Authors:  H Nagai; H Shishido; R Yoneda; E Yamaguchi; A Tamura; A Kurashima
Journal:  Respiration       Date:  1991       Impact factor: 3.580

10.  Prospective open-label evaluation of long-term low-dose doxycycline for difficult-to-treat chronic rhinosinusitis with nasal polyps.

Authors:  A C Pinto Bezerra Soter; T F Bezerra; R Pezato; T R Teles Abdo; R M Pilan; F R Pinna; P Gevaert; T van Zele; C Bachert; R L Voegels
Journal:  Rhinology       Date:  2017-06-01       Impact factor: 3.681

View more
  1 in total

1.  Meta-analysis of global and high throughput public gene array data for robust vascular gene expression discovery in chronic rhinosinusitis: Implications in controlled release.

Authors:  Nitish Khurana; Abigail Pulsipher; Hamidreza Ghandehari; Jeremiah A Alt
Journal:  J Control Release       Date:  2020-11-02       Impact factor: 9.776

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.